Enhancing the Expression of a Key Mitochondrial Enzyme at the Inception of Ischemia-reperfusion Injury Can Boost Recovery and Halt the Progression of Acute Kidney Injury
Overview
Authors
Affiliations
Hydrodynamic fluid delivery has shown promise in influencing renal function in disease models. This technique provided pre-conditioned protection in acute injury models by upregulating the mitochondrial adaptation, while hydrodynamic injections of saline alone have improved microvascular perfusion. Accordingly, hydrodynamic mitochondrial gene delivery was applied to investigate the ability to halt progressive or persistent renal function impairment following episodes of ischemia-reperfusion injuries known to induce acute kidney injury (AKI). The rate of transgene expression was approximately 33% and 30% in rats with prerenal AKI that received treatments 1 (T) and 24 (T) hours after the injury was established, respectively. The resulting mitochondrial adaptation exogenous IDH2 (isocitrate dehydrogenase 2 (NADP+) and mitochondrial) significantly blunted the effects of injury within 24 h of administration: decreased serum creatinine (≈60%, < 0.05 at T; ≈50%, < 0.05 at T) and blood urea nitrogen (≈50%, < 0.05 at T; ≈35%, < 0.05 at T) levels, and increased urine output (≈40%, < 0.05 at T; ≈26%, < 0.05 at T) and mitochondrial membrane potential, Δψ, (≈ by a factor of 13, < 0.001 at T; ≈ by a factor of 11, < 0.001 at T), despite elevated histology injury score (26%, < 0.05 at T1; 47%, < 0.05 at T). Therefore, this study identifies an approach that can boost recovery and halt the progression of AKI at its inception.
Kim M, Oh C, Hong C, Jeon J J Yeungnam Med Sci. 2024; 41(2):61-73.
PMID: 38351610 PMC: 11074843. DOI: 10.12701/jyms.2023.01347.
A proposed model of xeno-keratoplasty using 3D printing and decellularization.
Wang X, Elbahrawi R, Abdukadir A, Ali Z, Chan V, Corridon P Front Pharmacol. 2023; 14:1193606.
PMID: 37799970 PMC: 10548234. DOI: 10.3389/fphar.2023.1193606.
Pantic I, Cumic J, Valjarevic S, Shakeel A, Wang X, Vurivi H Front Bioeng Biotechnol. 2023; 11:1105377.
PMID: 37304146 PMC: 10250676. DOI: 10.3389/fbioe.2023.1105377.
Wang X, Shakeel A, Salih A, Vurivi H, Daoud S, Desidery L Front Bioeng Biotechnol. 2023; 11:1133122.
PMID: 37180037 PMC: 10168539. DOI: 10.3389/fbioe.2023.1133122.
Corridon P Sci Rep. 2023; 13(1):5289.
PMID: 37002341 PMC: 10066218. DOI: 10.1038/s41598-023-31747-w.